Richard P Slaughter Associates Inc Has $1.20 Million Position in Johnson & Johnson $JNJ

Richard P Slaughter Associates Inc boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.2% in the second quarter, Holdings Channel reports. The firm owned 7,866 shares of the company’s stock after purchasing an additional 596 shares during the period. Richard P Slaughter Associates Inc’s holdings in Johnson & Johnson were worth $1,202,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Highline Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the first quarter worth $49,000. Finally, Capital A Wealth Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $50,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Guggenheim reiterated a “neutral” rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Finally, Citigroup raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Trading Down 0.2%

NYSE JNJ opened at $178.10 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The business’s fifty day moving average is $170.81 and its 200-day moving average is $161.27. The stock has a market capitalization of $428.93 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the previous year, the business posted $2.82 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.